BOSTON, MA—The Reprieve decongestion management system (Reprieve Cardiovascular) appears to safely manage patients hospitalized with acute heart failure (HF) and significant volume overload, according ...
German-American medical device firm, Reprieve Cardiovascular, is eyeing up a pivotal trial with its cardiovascular drainage device after reporting success from a first-in-human study. Results from the ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
MILFORD, Mass. & FRANKFURT, Germany--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today ...
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the publication of results from its FASTR randomized ...
During the conference, Mr. Pacyna will discuss Reprieve’s recent corporate and clinical milestones, including the ongoing enrollment in the Company’s pivotal FASTR II clinical trial. The presentation ...
-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results